Highly Multiplexed Proteomic Analysis as a Translational Tool: Implications for Useful Biomarker Discovery and Early Clinical Development

摘要

A significant challenge in early clinical development of new therapeutics relates to the low predictive value of biomarkers derived from pre-clinical model systems in human disease. One approach to this issue is through the use of a rapid, highly multiplexed, quantitative assay solution targeted at human proteins and cross-species homologs. SOMAscan? , a high-throughput, multiplexed proteomic assay (>1100 protein analytes), is capable of simultaneously measuring proteins from small volumes of biological samples such as plasma, tissue or cell culture and has been successfully applied to clinical studies and multiple non-clinical model systems.